International Nonproprietary Names

Haselbeck, Anton
January 2010
WHO Drug Information;2010, Vol. 24 Issue 1, p21
Academic Journal
The article discusses the biochemical properties of epoetins, which are recombinant versions of human erythropoietin. The carbohydrate structure and glycosylation process of epoetins are described. All epoetins irrespective of their International Nonproprietary Name (INN) exhibit distinct glycosylation patterns, due largely to different production processes. The author notes that even minor differences in glycosylation can have an impact on drug pharmacokinetics and safety.


Related Articles

  • Erythropoiesis stimulating agents: approaches to modulate activity. Sinclair, Angus M. // Biologics: Targets & Therapy;2013, Vol. 7, p161 

    Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may...

  • Pharmacokinetics and Pharmacodynamics of Recombinant Human EPO-Fc Fusion Protein In Vivo. Shi, Xunlong; Yang, Jianjun; Zhu, Haiyan; Ye, Li; Feng, Meiqing; Li, Jiyang; Huang, Hai; Tao, Qun; Ye, Dan; Sun, Lee-Hwei K.; Sun, Bill N. C.; Sun, Cecily R. Y.; Han, Guizhen; Liu, Yuanyuan; Yao, Minghui; Zhou, Pei; Ju, Dianwen // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    In this study, the in vivo pharmacokinetics and pharmacodynamics of a novel recombinant human erythropoietin (rhEPO) Fc fusion protein, rhEPO-Fc, were studied in both rodents and rhesus monkeys. Animal models of anemia induced by irradiation, cyclophosphamide and partial renal ablation were...

  • Pharmacokinetic-Pharmacodynamic Modelling of Recombinant Human Erythropoietin in Athletes: A Population Approach. Gaudard, A. GaudardA.; Varlet-Marie, E.; Audran, M.; Gomeni, R.; Bressolle, F. // Clinical Drug Investigation;2003, Vol. 23 Issue 3, p167 

    Objective: To develop a pharmacokinetic model able to take into account the negative feedback loop of endogenous erythropoietin production observed after repeated administration of recombinant human erythropoietin (rHuEPO), and to propose a pharmacokinetic-pharmacodynamic model capable of...

  • Pharmacokinetics/Pharmacodynamics of Recombinant Human Erythropoietins in Doping Control. Varlet-Marie, Emmanuelle; Gaudard, Aurélie; Audran, Michel; Bressolle, Francoise // Sports Medicine;2003, Vol. 33 Issue 4, p301 

    The purpose of this paper is: (i) to compare recombinant human erythropoietin (rHuEPO) pharmacokinetics in athletes and healthy individuals; and (ii) to report pharmacokinetic/pharmacodynamic (PK/PD) studies performed in athletes. Effect parameters in PK/PD studies included: (i) red blood cell...

  • EMEA Guidelines on Biosimilars and Their Clinical Implications. Rossert, Jerome // Kidney & Blood Pressure Research;Jul2007, Vol. 30 Issue S1, p13 

    The article summarizes the guidelines on recombinant human erythropoietin issued by the European Agency for the Evaluation of Medicinal Products and their implications. Various studies on recombinant human erythropoietin still need to be conducted, including human pharmacokinetic and...

  • Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor Polymorphisms. O'Connor, Christopher M.; Fiuzat, Mona; Carson, Peter E.; Anand, Inder S.; Plehn, Jonathan F.; Gottlieb, Stephen S.; Silver, Marc A.; Lindenfeld, JoAnn; Miller, Alan B.; White, Michel; Walsh, Ryan; Nelson, Penny; Medway, Allen; Davis, Gordon; Robertson, Alastair D.; Port, J. David; Carr, James; Murphy, Guinevere A.; Lazzeroni, Laura C.; Abraham, William T. // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    Background: Pharmacogenetics involves complex interactions of gene products affecting pharmacodynamics and pharmacokinetics, but there is little information on the interaction of multiple genetic modifiers of drug response. Bucindolol is a β-blocker/sympatholytic agent whose efficacy is...

  • Elimination of β-mannose glycan structures in Pichia pastoris. Hopkins, Daniel; Gomathinayagam, Sujatha; Rittenhour, Alissa M; Du, Min; Hoyt, Erik; Karaveg, Khanita; Mitchell, Teresa; Nett, Juergen H; Sharkey, Nathan J; Stadheim, Terrance A; Li, Huijuan; Hamilton, Stephen R // Glycobiology;Dec2011, Vol. 21 Issue 12, p1616 

    The methylotrophic yeast, Pichia pastoris, is an important organism used for the production of therapeutic proteins. However, the presence of fungal-like glycans, such as those containing β-mannose (Man) linkages, can elicit an immune response or bind to Man receptors, thus reducing their...

  • Current state and perspectives on erythropoietin production. Lee, Jae; Ha, Tae; Lee, Seung; Lee, Gyun // Applied Microbiology & Biotechnology;Sep2012, Vol. 95 Issue 6, p1405 

    Erythropoietin is a major regulator of erythropoiesis which maintains the body's red blood cell mass and tissue oxygenation at an optimum level. Recombinant human erythropoietin (rhEPO), which is a widely used therapeutic agent for the treatment of anemia and which represents one of the largest...

  • Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact. Kiss, Zoltán; Elliott, Steven; Jedynasty, Kinga; Tesar, Vladimír; Szegedi, János // European Journal of Clinical Pharmacology;Apr2010, Vol. 66 Issue 4, p331 

    Cloning of the human erythropoietin ( EPO) gene and development of the first recombinant human erythropoietin (rHuEPO) drug were truly breakthroughs. This allowed a deeper understanding of the structure and pharmacology of rHuEpo, which in turn inspired the discovery and development of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics